The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles
Cadron I, Van Gorp T, Amant F, Vergote I, Moerman P, Waelkens E, Daemen A, Van De Plas R, De Moor B, Zeillinger R.
Anticancer Research 29(4): 1039-45,2009.

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO
Sehouli J, Stengel D, Mustea A, Camara O, Keil E, Elling D, Ledwon P, Christiansen B, Klare P, Gebauer G, Schwarz M, Lichtenegger W; on behalf of the Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO).
Cancer Chemother Pharmacol. 2008 Feb;61(2):243-50. Epub 2007 Mar 29.

Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J.
Gynecol Oncol. 2007 Nov;107(2):266-73. Epub 2007 Aug 14.

The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies
Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Krüger A, Altevogt P.
Oncogene. 2007 Oct 22

Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study
Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J
Support Care Cancer. 2007 Aug 7; [Epub ahead of print]

External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group
Van Holsbeke C, Van Calster B, Valentin L, Testa AC, Ferrazzi E, Dimou I, Lu C, Moerman P, Van Huffel S, Vergote I, Timmerman D; International Ovarian Tumor Analysis Group
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4440-7.

The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer
Cadron I, Leunen K, Amant F, Van Gorp T, Neven P, Vergote I
Gynecol Oncol. 2007 Aug;106(2):354-61. Epub 2007 May 11

Management of borderline ovarian neoplasms.
Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I
J Clin Oncol. 2007 Jul 10;25(20):2928-37

Characterization of protein-interaction networks in tumors
Platzer A, Perco P, Lukas A, Mayer B.
BMC Bioinformatics. 2007 Jun 27;8:224.

Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study
Mustea A, Sehouli J, Fabjani G, Koensgen D, Möbus V, Braicu EI, Pirvulescu C, Thomas A, Tong D, Zeillinger R
Anticancer Res. 2007 May-Jun;27(3B):1527-30.

Vascular endothelial growth factor gene polymorphisms in ovarian cancer.
Polterauer S, Grimm C, Mustea A, Concin N, Tanner B, Thiel F, Heinze G, Reinthaller A, Zeillinger R, Hefler LA
Gynecol Oncol. 2007 May;105(2):385-9. Epub 2007 Feb 6

Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany.
Chekerov R, Denkert C, Boehmer D, Suesse A, Widing A, Ruhmland B, Giese A, Mustea A, Lichtenegger W, Sehouli J.
Int J Gynecol Cancer. 2007 Apr 27; [Epub ahead of print

The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma
Fuchs I, Vorsteher N, Bühler H, Evers K, Sehouli J, Schaller G, Kümmel S
Anticancer Res. 2007 Mar-Apr;27(2):959-63

A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
Obermair A, Fuller A, Lopez-Varela E, van Gorp T, Vergote I, Eaton L, Fowler J, Quinn M, Hammond I, Marsden D, Proietto A, Carter J, Davy M, Tripcony L, Abu-Rustum N.
Gynecol Oncol. 2007 Mar;104(3):607-11. Epub 2006 Nov 7.

Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients.
Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Könsgen D, Sun P, Nürnberg P, Lichtenegger W, Sehouli J.
Gynecol Oncol. 2007 Mar;104(3):680-5. Epub 2006 Dec 1

Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients
Oskay-Ozcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Bamberg M, Wallwiener D, Overkamp F, Diedrich K, von Minckwitz G, Höffken K, Seeber S, Mirz R, Sehouli J.
Ann Oncol. 2007 Mar;18(3):479-84. Epub 2007 Feb 1.

The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.
Sun PM, Wei LH, Luo MY, Liu G, Wang JL, Mustea A, Könsgen D, Lichtenegger W, Sehouli J.
Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):249-57. Epub 2006 Mar 7.

Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG.
Cancer. 2007 Feb 15;109(4):645-9.

L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells
Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P, Altevogt P.
Gynecol Oncol. 2007 Feb;104(2):461-9.

Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.
Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R, Heinze G, Grimm C, Schuster E, Tempfer C, Reinthaller A, Zeillinger R.
Clin Cancer Res. 2007 Feb 1;13(3):898-901

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.
Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Hefler L, Horvat R, Reinthaller A, Zeillinger R, Krainer M.
Br J Cancer. 2007 Feb 12;96(3):485-91. Epub 2007 Jan 23

Efficient adsorption of tumor necrosis factor with an in vitro set-up of the microspheres-based detoxification system
Weber V, Hartmann J, Linsberger I, Falkenhagen D.
Blood Purif. 2007;25(2):169-74. Epub 2007 Jan 5

Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis
Knogler K, Grünberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, Altevogt P, Fogel M, Schubiger PA, Novak-Hofer I.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):603-11.

Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer
Vandenput I, Amant F, Neven P, Berteloot P, Leunen K, Vergote I.
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):83-7

The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer.
Van Gorp T, Amant F, Neven P, Berteloot P, Leunen K, Vergote I.
Cancer Treat Res. 2007;134:387-402.

Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors
Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Könsgen D, Dietel M, Fiehn O.
Cancer Res. 2006 Nov 15;66(22):10795-804

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer
Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A.
Gynecol Oncol. 2006 Nov;103(2):512-7. Epub 2006 Jun 5

Intraperitoneal chemotherapy in ovarian cancer remains experimental
Gore M, du Bois A, Vergote I.
J Clin Oncol. 2006 Oct 1;24(28):4528-30

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).
Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg ME; EORTC Gynaecological Cancer Group.
Eur J Cancer. 2006 Oct;42(15):2539-48. Epub 2006 Sep 11

The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
Van Gorp T, Amant F, Neven P, Berteloot P, Leunen K, Vergote I.
Minerva Ginecol. 2006 Oct;58(5):393-403.

Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?
du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J; Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR; AGO Study Group Ovarian Cancer [AGO-OVAR]; Norddeutsche Gesellschaft Fuer Gynaekologische Onkologie [NOGGO].
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1756-60

The management of borderline tumours of the ovary
Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I
Curr Opin Oncol. 2006 Sep;18(5):488-93

Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines.
Escrevente C, Machado E, Brito C, Reis CA, Stoeck A, Runz S, Marmé A, Altevogt P, Costa J
Int J Oncol. 2006 Sep;29(3):557-66.

Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
Vergote I, Amant F.
Gynecol Oncol. 2006 Sep;102(3):415-7

Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy
Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M.
Hum Pathol. 2006 Aug;37(8):1000-8.

L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells
Stoeck A, Schlich S, Issa Y, Gschwend V, Wenger T, Herr I, Marmé A, Bourbie S, Altevogt P, Gutwein P.
Cancer Lett. 2006 Aug 8;239(2):212-26. Epub 2005 Dec 27.

Mismatch repair and treatment resistance in ovarian cancer
Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM.
BMC Cancer. 2006 Jul 31;6:201

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial
Sehouli J, Oskay-Ozcelik G, Kühne J, Stengel D, Hindenburg HJ, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO).
Ann Oncol. 2006 Jun;17(6):957-61. Epub 2006 Apr 6.

Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study.
Gonçalves A, Delva R, Fabbro M, Gladieff L, Lotz JP, Ferrero JM, Linassier C, Cottu PH, Viens P, Extra JM
Bone Marrow Transplant. 2006 Apr;37(7):651-9

Molecular profiling of platinum resistant ovarian cancer.
Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM.
Int J Cancer. 2006 Apr 15;118(8):1963-71

A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer
Six L, Grimm C, Leodolter S, Tempfer C, Zeillinger R, Sliutz G, Speiser P, Reinthaller A, Hefler LA.
Gynecol Oncol. 2006 Mar;100(3):506-10. Epub 2005 Oct 6.

Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J
Anticancer Res. 2006 Mar-Apr;26(2C):1683-9.

Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report.
Sehouli J, Stupin JH, Schlieper U, Kuemmel S, Henrich W, Denkert C, Dietel M, Lichtenegger W.
Anticancer Res. 2006 Mar-Apr;26(2C):1727-31

Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes
Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G, Zeiser T, Ulm K, Kobl M, Korlach S, Schmid P, Sehouli J, Elling D, Blohmer JU.
Anticancer Res. 2006 Mar-Apr;26(2C):1719-26.

Expression of IL-10 in patients with ovarian carcinoma
Mustea A, Könsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J
Anticancer Res. 2006 Mar-Apr;26(2C):1715-8.

Postoperative therapy modalities for cervical carcinoma
Kümmel S, Thomas A, Jeschke S, Hauschild M, Sehouli J, Lichtenegger W, Blohmer JU
Anticancer Res. 2006 Mar-Apr;26(2C):1707-13

Chordin is underexpressed in ovarian tumors and reduces tumor cell motility
Moll F, Millet C, Noël D, Orsetti B, Bardin A, Katsaros D, Jorgensen C, Garcia M, Theillet C, Pujol P, François V.
FASEB J. 2006 Feb;20(2):240-50

Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients.
Fuso L, Amant F, Neven P, Berteloot P, Vergote I.
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:60-7

Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment
Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grünberg J, Honer M, Schubiger PA, Altevogt P, Krüger A.
Cancer Res. 2006 Jan 15;66(2):936-43.

Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.
Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E.
Neoplasia. 2006 Jan;8(1):38-45

Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, Zielinski CC, Horvat R, Zeillinger R, Reinthaller A, Krainer M
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8585-91

Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group
Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L; International Ovarian Tumor Analysis Group.
J Clin Oncol. 2005 Dec 1;23(34):8794-801.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo
Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R
Clin Cancer Res. 2005 Dec 1;11(23):8372-83

Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival
Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus VJ, Zielinski C, Reinthaller A, Zeillinger R, Krainer M.
Cancer. 2005 Dec 1;104(11):2417-29.

Neoadjuvant chemotherapy for ovarian cancer.
Vergote I, van Gorp T, Amant F, Neven P, Berteloot P.
Oncology (Williston Park). 2005 Nov;19(12):1615-22; discussion 1623-30.

Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma
Vergote I, Marquette S, Amant F, Berteloot P, Neven P.
Int J Gynecol Cancer. 2005 Sep-Oct;15(5):776-9

L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas
Gast D, Riedle S, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y, Stoeck A, Fogel M, Joumaa S, Wenger T, Herr I, Gutwein P, Altevogt P.
Int J Cancer. 2005 Jul 1;115(4):658-65

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer
Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C, Krainer M
Mol Cancer Res. 2005 Jun;3(6):335-43

Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.
Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, Wei L, Lichtenegger W.
J Mol Med.
2005 Jun;83(6):457-67. Epub 2005 Mar 16.

Review of gemcitabine-based combinations for platinum-resistant ovarian cancer
Sehouli J.
Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:23-30

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer
Horak P, Pils D, Roessler M, Tomek S, Elandt K, Zeillinger R, Zielinski C, Krainer M.
Gynecol Oncol. 2005 May;97(2):514-8.

Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells
Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marmé A, Phong MC, Linderkamp O, Skorokhod A, Altevogt P.
Clin Cancer Res. 2005 Apr 1;11(7):2492-501.

Biochip for K-ras mutation screening in ovarian cancer
Fabjani G, Kriegshaeuser G, Schuetz A, Prix L, Zeillinger R.
Clin Chem. 2005 Apr;51(4):784-7

Transthyretin, a biomarker for nutritional status and ovarian cancer.
Schweigert FJ, Sehouli J.
Cancer Res. 2005 Feb 1;65(3):1114; author reply 1114

Why institutions do not participate in ovarian cancer trials -- results from a survey in Germany
Sehouli J, Kostromitskaia J, Stengel D, Bois A
Onkologie. 2005 Jan;28(1):13-7